EPS: As of FY2025 Q2, the actual value is USD -1.31.

EBIT: As of FY2025 Q2, the actual value is USD -247.79 M.

Segment Revenue

• Research and Development Expenses: $224.1 million for the three months ended June 30, 2025, compared to $134.9 million for the same period in 2024, representing a 66% increase. For the six months ended June 30, 2025, expenses were $429.9 million, compared to $252.9 million in 2024, a 70% increase.

Operational Metrics

• Net Loss: $247.8 million for the three months ended June 30, 2025, compared to $133.2 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $461.2 million, compared to $249.2 million in 2024.
• General and Administrative Expenses: $40.6 million for the three months ended June 30, 2025, compared to $21.7 million for the same period in 2024, an 87% increase. For the six months ended June 30, 2025, expenses were $75.6 million, compared to $44.5 million in 2024, a 70% increase.

Cash Flow

• Net Cash Used in Operating Activities: - $416.2 million for the six months ended June 30, 2025, compared to - $288.7 million for the same period in 2024.
• Net Cash Provided by Investing Activities: $18.3 million for the six months ended June 30, 2025, compared to - $140.0 million used in 2024.
• Net Cash Provided by Financing Activities: $257.5 million for the six months ended June 30, 2025, compared to $8.3 million in 2024.

Unique Metrics

• Liability Related to the Sale of Future Royalties: $245.1 million as of June 30, 2025, resulting from a $250.0 million upfront payment received under the Royalty Purchase Agreement.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue advancing its RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, through clinical development. It expects to initiate several pivotal trials in 2025 and 2026, including a global, randomized Phase 3 study of daraxonrasib in first-line metastatic PDAC and a monotherapy study as adjuvant treatment for resectable PDAC.
• Non-Core Business: The company is exploring various strategic collaborations, including with Tango Therapeutics and Summit Therapeutics, to evaluate combination therapies involving its RAS(ON) inhibitors.